NASD · Healthcare · Biotechnology · USA
Aligos Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Aligos Therapeutics is a clinical-stage biotechnology company developing drug candidates for liver diseases and viral infections. Its current pipeline includes pevifoscorvir sodium for chronic hepatitis B, ALG-055009 for metabolic dysfunction-associated steatohepatitis and obesity, and ALG-097558 for coronavirus infections, along with preclinical programs targeting these therapeutic areas.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Aligos Therapeutics Inc stock.
Undervalued: intrinsic value $6.79 per share, market price $1.36, margin of safety 80.0% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $6.79; the price of $1.36 is 80% below that value.
4 more funds hold it; the full list is part of the paid plan.
ALGS is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $6.79; the price of $1.36 is 80% below that value.
$6.79 per share (as of the 2026-11-17 close), against a market price of $1.36. That is a margin of safety of 80.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.